Among the molecular partners required for tumor formation on the PTEN loss background, the studies have identified mammalian target of rapamycin complex 2 (mTORC2) and phosphoinositide 3-kinase (PI3K) isoform p110β [69,70]. This evidence concerns the gene PTEN and neoplasm.